Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.60 |
| ▸ | CTSK | P43235 | 2/20 | 0.60 |
| ▸ | CTSB | P07858 | 1/20 | 0.60 |
| ▸ | CTSS | P25774 | 1/20 | 0.60 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55833 | 1.00 | CTSL (0.60) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL56907 | 1.00 | CTSL (0.60) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL1026997 | 0.94 | CTSL (0.62) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL1176795 | 0.94 | CTSL (0.62) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL1026994 | 0.94 | CTSL (0.62) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL21675512 | 0.91 | CTSK (0.61) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL23080082 | 0.90 | CTSL (0.54) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL16668218 | 0.90 | CTSL (0.54) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL6897731 | 0.90 | CTSK (0.60) | CTSLCTSKCTSBCTSSCAPN1 | |
| SCHEMBL12588811 | 0.89 | CTSL (0.53) | CTSLCTSKCTSBCTSSCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4685151-A1 | PROTEASOME INHIBITOR | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025030117-A1 | FERROPTOSIS INDUCERS | ARPEGGIO BIOSCIENCES, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116670143-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4225447-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116601161-A | Prodrugs of 2- (3, 5-dichloro-1-methyl-indazol-4-yl) -1- [ (1 s,3 r) -3- (hydroxymethyl) -5- (1-hydroxy-1-methyl-ethyl) -1-methyl-3, 4-dihydro-1H-isoquinolin-2-yl ] ethanone | UCB生物制药有限责任公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-0601486-A1 | Cis-epoxide derivatives useful as irreversible HIV protease inhibitors and process and intermediates for their preparation | LUCKY LTD. (KR) | 1994-06-15 | — | — | EP | disclosed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0212903-B1 | POLYPEPTIDE DERIVATIVES CONTAINING 5-AMINO-2,5-DISUBSTITUTED-4-HYDROXYPENTANOIC ACID RESIDUES | PFIZER INC. (US) | 1992-12-30 | — | — | EP | disclosed |
| US-5122610-A | Renin inhibitor intermediates | BAYER AKTIENGESELLSCHAFT (DE) | 1992-06-16 | — | — | US | disclosed |
| US-4992562-A | Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues | PFIZER INC. (US) | 1991-02-12 | — | — | US | disclosed |
| US-4948913-A | Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues | PFIZER INC. (US) | 1990-08-14 | — | — | US | disclosed |
| EP-0356796-A2 | Aminomethyl peptides, production process and their use as medicaments | BAYER AG (DE) | 1990-03-07 | — | — | EP | disclosed |
| EP-0310918-A2 | Peptide-like amino-acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-04-12 | — | — | EP | disclosed |
| US-4729985-A | Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues | PFIZER INC. (US) | 1988-03-08 | — | — | US | disclosed |
| EP-0212903-A2 | Polypeptide derivatives containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues | PFIZER INC. (US) | 1987-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CTSL 3165/4885CTSK 2874/4885CTSB 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.